F Glaser
University of Hamburg
7 Papers
1 Citations
F Glaser is an academic researcher from University of Hamburg. The author has contributed to research in topics: Medicine & Antibody. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
SARS‐CoV‐2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease
P. Duengelhoef,Johannes Hartl,D. Rüther,Silja Steinmann,Thomas Theo Brehm,J.P. Weltzsch,F Glaser,G. Schaub,Martina Sterneck,Marcial Sebode,Christina Weiler-Normann,Marylyn M. Addo,Marc Lütgehetmann,Friedrich Haag,Christoph Schramm,Julian Schulze zur Wiesch,Ansgar W. Lohse +16 more
TL;DR: Patients with AIH show an increased Sars‐CoV‐2 infection rate as well as an impaired B‐ and T‐cell response to SARS‐Cov‐2 vaccine compared to PBC and PSC patients, even in the absence of immunosuppression, and antibody responses to vaccination in AIH patients need to be monitored.
37
Liver infiltrating T cells regulate bile acid metabolism in experimental cholangitis.
F Glaser,Clara John,Bastian Engel,B Höh,Sören Weidemann,Jan Dieckhoff,S Stein,Nathalie Becker,Christian Casar,Fenja Amrei Schuran,Björn Wieschendorf,M Preti,Friederike Jessen,Andre Franke,Antonella Carambia,Ansgar W. Lohse,Harald Ittrich,Johannes Herkel,Joerg Heeren,Christoph Schramm,Dorothee Schwinge +20 more
TL;DR: Dysregulation of bile acid metabolism as well as of T cells could contribute to the development of cholangiopathies and understanding the effect of lymphocytes on BA metabolism will help to design combined treatment strategies for cholestatic liver diseases.
34
Analysis of the humoral and cellular response after the third COVID‐19 vaccination in patients with autoimmune hepatitis
Johannes Hartl,D. Rüther,P. Duengelhoef,Thomas Theo Brehm,Silja Steinmann,J.P. Weltzsch,F Glaser,Martina Sterneck,Marcial Sebode,Christina Weiler-Normann,Marc Lütgehetmann,G. Schaub,Friedrich Haag,Christoph Schramm,Julian Schulze zur Wiesch,Ansgar W. Lohse +15 more
TL;DR: A third COVID‐19 vaccination efficiently boosts antibody levels and T‐cell responses in AIH patients and even seroconversion in patients with absent immune response after two vaccinations, but to a lower level compared to controls.
13
PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease
Lorenz Kocheise,Ignazio Piseddu,Joscha Vonderlin,Eric T. Tjwa,Gustav Buescher,Lucy Meunier,Pia Goeggelmann,Francesca Fianchi,Jérôme Dumortier,Mar Riveiro Barciela,Tom J. G. Gevers,Benedetta Terziroli Beretta-Piccoli,Maria-Carlota Londoño,Sona Frankova,Thomas G. Roesner,Vincent Joerg,Constantin Schmidt,F Glaser,Jan P. Sutter,T Fründt,Ansgar W. Lohse,Samuel Huber,Johann von Felden,Marcial Sebode,Kornelius Schulze +24 more
TL;DR: This European multicenter study demonstrates that PD-1/PD-L1 inhibitors appear to be safe in patients with AILD and concludes that immunotherapy should not categorically be withheld from patients with AILD.
1
Low antibody titers after second SARS-CoV-2 vaccination in patients with autoimmune hepatitis
Paul Düngelhoef,Johannes Hartl,D. Rüther,Silja Steinmann,Manmeet Kaur,F Glaser,Martina Sterneck,Marcial Sebode,Christina Weiler-Normann,Marc Lütgehetmann,Christoph Schramm,Julian Schulze zur Wiesch,Ansgar W. Lohse +12 more
TL;DR: Despite high seroconversion rates, AIH patients show a significantly reduced magnitude of the humoral immune response to SARS-CoV-2 vaccination, suggesting thatAIH patients should be recommended an early third booster shot in agreement with recent advice by the German STIKO.
1